Combination of resveratrol and fetal liver stem cell transplantation for treatment of liver cirrhosis in rats

doi:10.3969/j.issn.2095-4344.1644

Abstract

Abstract:

BACKGROUND: Low-dose resveratrol can promote cell activation and show synergy with fetal liver stem cell transplantation for liver cirrhosis in rats.
OBJECTIVE: To observe and investigate the effects of resveratrol and fetal liver stem cell transplantation on the rat with liver cirrhosis.
METHODS: Eighty-four Sprague-Dawley adult rats were intragastrically administered with carbon tetrachloride to induce liver cirrhosis, and the animal model of liver cirrhosis was successfully made in 81 rats. After the successful modeling, 80 of the 81 model rats were randomly divided into four groups (n=20/group): the rats in the control group were injected with 0.5 mL of low-dose Dulbecco’s modified Eagle’s medium into the tail vein; the rats in the fetal liver stem cell group were injected with 0.5 mL of fetal liver stem cell suspensions into the tail vein; the rats in the resveratrol group was intragastrically administered with 120 mg/kg resveratrol; and the rats in the combination group were given injection of fetal liver stem cell suspension and administration of resveratrol. All treatments were given once daily for 7 consecutive days. After 3 weeks of treatment, the indocyanine green excretion test was used to determine the 15-minute retention rate of indocyanine green. The biochemical indicators of the serum and liver tissues were detected by an automatic biochemical analyzer. Morphological changes of the liver tissue were observed by hematoxylin-eosin staining. Transforming growth factor β1 gene and protein expression in the liver tissue was detected by RT-PCR and western blot, respectively.
RESULTS AND CONCLUSION: (1) Compared with the control group, the levels of serum alanine aminotransferase, serum aspartate aminotransferase, serum total bilirubin and malondialdehyde in the liver tissue were significantly reduced in the fetal liver stem cell group and resveratrol group (P < 0.01), while serum albumin level, total protein level, albumin/globulin, and glutathione peroxidase level and cyclic guanosine monophosphate level in the liver tissue were significantly increased in these two groups (P < 0.05). These aforementioned biochemical indicators in the combination group were significantly improved as compared with the fetal liver stem cells group and resveratrol group (P < 0.05). (2) Hepatocyte degeneration, necrosis and fibrosis were significantly reduced in the three treatment groups, especially in the combination group. (3) Compared with the control group, the 15-minute retention rate of indocyanine green was significantly increased after resveratrol intervention and fetal liver stem cell transplantation (P < 0.05), and further increased after combination treatment (P < 0.01). (4) Compared with the control group, the expression of transforming growth factor β1 was significantly decreased in the resveratrol group and fetal liver stem cell group (P < 0.05), and further decreased in the combination group (P < 0.01). To conclude, resveratrol treatment combined with fetal liver stem cell transplantation can effectively improve the levels of blood biochemical markers and significantly reduce the degree of liver cirrhosis and hepatic histopathological changes in the rats with liver cirrhosis. This may be related to the decreased expression of transforming growth factor β1 gene and protein.

Key words: Liver Cirrhosis, Liver, Stem Cell Transplantation, Transforming Growth Factor beta1, Tissue Engineering

CLC Number:

Wang Yuxuan. Combination of resveratrol and fetal liver stem cell transplantation for treatment of liver cirrhosis in rats[J]. Chinese Journal of Tissue Engineering Research, 2019, 23(13): 2049-2054.

Figures/Tables 5

References

[1] 马雄.原发性胆汁性肝硬化诊治进展[J].临床肝胆病杂志, 2016, 32(4):21-22.

[2] 田耀洲.难治性原发性胆汁性肝硬化治疗进展[C]. 重庆:中华中医药学会脾胃病分会第二十七届全国脾胃病学术交流会,2015.

[3] 张静雯,时永全,韩英.肝硬化的治疗进展[J].临床肝胆病杂志, 2015,31(3):465-468.

[4] O'Grady JG. Liver transplantation. Jama. 2015; 43(11): 686-688.

[5] Pangeni R, Sahni JK, Ali J, et al. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014;11(8):1285-1298.

[6] Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver: A systematic review. J Res Med Sci. 2015;20(8):797-810.

[7] 罗德兰,杨丹,舒梅铃,等.白藜芦醇抗肝癌作用机制的研究进展[J].世界华人消化杂志,2014, 22(31):4769-4773.

[8] Chan CC, Lee KC, Huang YH, et al. Regulation by resveratrol of the cellular factors mediating liver damage and regeneration after acute toxic liver injury. J Gastroenterol Hepatol. 2014;29(3):603-613.

[9] Tang Y, Gan X, Cheheltani R, et al. Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model. Nanomedicine. 2014; 10(8):1711-1718.

[10] Atashi F, Modarressi A, Pepper MS. The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review. Stem Cells Dev. 2015; 24(10):1150-1163.

[11] Jeong H, Yim HW, Cho YS, et al. Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis. Int J Stem Cells. 2014;7(2):63-69.

[12] Bruin JE, Saber N, Braun N, et al. Treating diet-induced diabetes and obesity with human embryonic stem cell-derived pancreatic progenitor cells and antidiabetic drugs. Stem Cell Reports. 2015;4(4):605-620.

[13] Morigi M, De Coppi P. Cell therapy for kidney injury: different options and mechanisms--mesenchymal and amniotic fluid stem cells. Nephron Exp Nephrol. 2014;126(2):59.

[14] 陆炼,于兵,胡以平.肝干细胞研究进展[J].第二军医大学学报, 2017,38(4):493-500.

[15] Hardin H, Yu XM, Harrison AD, et al. Generation of Novel Thyroid Cancer Stem-Like Cell Clones: Effects of Resveratrol and Valproic Acid. Am J Pathol. 2016;186(6):1662-1673.

[16] 韩海燕,宋文广.脂肪间充质干细胞移植后肝硬化大鼠血生化指标的变化[J].中国组织工程研究,2016,20(36):5364-5370.

[17] Singh A, Ahmad I, Iqbal Z, et al. Resveratrol nanoparticles improve oral delivery and arrests the progression of paracetamol-induced liver cirrhosis:stability assessment, in-vitro and in-vivo studies. National Biotechnology Conference.2015.

[18] Habeeb MA, Vishwakarma SK, Bardia A, et al. Hepatic stem cells: A viable approach for the treatment of liver cirrhosis. World J Stem Cells. 2015;7(5):859-865.

[19] Ulrich H. Stem Cell Reviews and Reports: Induced Pluripotent Stem Cells, Embryonic Stem Cells and Development Section. Stem Cell Rev. 2017;13(1):3.

[20] Zhang H, Zhai Z, Wang Y, et al. Resveratrol ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice. Free Radic Biol Med. 2013;54:40-50.

[21] Rimmelé P, Lofek-Czubek S, Ghaffari S. Resveratrol increases the bone marrow hematopoietic stem and progenitor cell capacity. Am J Hematol. 2014;89(12): E235-238.

[22] 李静,杨雅娟,李常娟,等.牛磺酸对四氯化碳所致大鼠肝硬化门静脉高压的影响[J].中国中医药信息杂志,2016,23(9):65-69.

[23] 陈振宙,张雪丹.熊果酸对四氯化碳所致大鼠肝纤维化及门静脉高压的影响[J].安徽医药,2017,21(4):635-639.

[24] 吴志强,王卫东,林杰,等.吲哚菁绿清除试验在肝癌术前评估肝脏储备功能的临床应用[J].岭南现代临床外科, 2015,15(4): 389-393.

[25] 杨博,罗庆,康权,等.TNF-α、TGF-β1在胆汁淤积性肝硬化中平衡调控肝脏干细胞分化[J].南方医科大学学报, 2018,38(4): 375-383.

[26] El-Youssef M, Mu Y, Huang L, et al. Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr. 1999;28(4):386-392.

[27] Tang LY, Heller M, Meng Z, et al. Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway. J Biol Chem. 2017;292(10):4302-4312.

[28] Ji H, Minuk GY, Peng Z, et al. Active immunization against transforming growth factor beta1 prevents hepatic fibrosis in a rat model of liver disease. Can J Physiol Pharmacol. 2017; 95(6):743-749.

[29] Wang Y, Zhao L, Jiao FZ, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-β1 signal pathway. Hepatobiliary Pancreat Dis Int. 2018;17(5):423-429.

[30] Liu F, Zhang J, Qian J, et al. Emodin alleviates CCl4?induced liver fibrosis by suppressing epithelial?mesenchymal transition and transforming growth factor?β1 in rats. Mol Med Rep. 2018;18(3):3262-3270.